Retrospective Medical Chart Review Study for Non-valvular Atrial Fibrillation Patients Treated or Untreated With Oral Anticoagulant in the National Cerebral and Cardiovascular Center (NCVC) in Japan
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 11,776
- 试验地点
- 1
- 主要终点
- Distribution of outcomes of NVAF participants: Smoking information
研究概览
简要总结
The purpose of this observational study is to understand real-world oral anticoagulants (OAC) (warfarin, apixaban, dabigatran, edoxaban and rivaroxaban) usage for non-valvular atrial fibrillation (NVAF) patients.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Retrospective
入排标准
- 年龄范围
- 20 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Participants received medical treatment for NVAF between 10-Jan-2012 and 31-Aug-2020.
排除标准
- •Had no data of serum creatinine in the participant's medical records
- •Had no data of body weight in the participant's medical records
- •Were given oral anticoagulant (OAC) for treatment of diseases other than atrial fibrillation (AF)
- •Other protocol-defined inclusion/exclusion criteria apply.
结局指标
主要结局
Distribution of outcomes of NVAF participants: Smoking information
时间窗: At Baseline
Distribution of outcomes of NVAF participants: Pulse rate
时间窗: At Baseline
Distribution of socio-demographic characteristics of NVAF participants: Age group
时间窗: At Baseline
Distribution of socio-demographic characteristics of NVAF participants: Height
时间窗: At Baseline
Distribution of outcomes of NVAF participants: Degree of life freedom
时间窗: At Baseline
Distribution of clinical characteristics of NVAF participants: Risk factors for bleeding
时间窗: At Baseline
Distribution of medication prescribed during baseline: angiotensin-converting enzyme inhibitor (ACE)
时间窗: At Baseline
Distribution of medication prescribed during baseline: Antiarrhythmic drug
时间窗: At Baseline
Distribution of medication prescribed during baseline: H2-receptor antagonist
时间窗: At Baseline
Distribution of clinical characteristics of NVAF participants: Comorbidities
时间窗: At Baseline
Specialization of the treating physician
时间窗: At Baseline
Distribution of socio-demographic characteristics of NVAF participants: Gender
时间窗: At Baseline
Distribution of outcomes of NVAF participants: Systolic and diastolic blood pressure
时间窗: At Baseline
Distribution of medication prescribed during baseline: angiotensin-receptor blocker (ARB)
时间窗: At Baseline
Distribution of outcomes of NVAF participants: Hospitalization/outpatient status
时间窗: At Baseline
Distribution of socio-demographic characteristics of NVAF participants: Body weight
时间窗: At Baseline
Distribution of outcomes of NVAF participants: Drinking information
时间窗: At Baseline
Distribution of clinical characteristics of NVAF participants: Risk factors for stroke
时间窗: At Baseline
Distribution of outcomes of NVAF participants: OAC prescription and administration status
时间窗: At Baseline
Distribution of medication prescribed during baseline: Statin
时间窗: At Baseline
Distribution of medication prescribed during baseline: P2Y12 inhibitor
时间窗: At Baseline
Distribution of medication prescribed during baseline: Other antiplatelet drugs
时间窗: At Baseline
Distribution of medication prescribed during baseline: Other anticoagulants
时间窗: At Baseline
Distribution of socio-demographic characteristics of NVAF participants: Body mass index (BMI)
时间窗: At Baseline
Distribution of outcomes of NVAF participants: Internal medical device information
时间窗: At Baseline
Distribution of medication prescribed during baseline: calcium antagonist
时间窗: At Baseline
Distribution of medication prescribed during baseline: proton pump inhibitor (PPI)
时间窗: At Baseline
Distribution of medication prescribed during baseline: aspirin
时间窗: At Baseline
Distribution of medication prescribed during baseline: P-glycoprotein inhibitor
时间窗: At Baseline
次要结局
未报告次要终点